

Special Issue

The Role of Immune Response During Viral Infection in Patients with Respiratory Allergy

Message from the Guest Editors

Respiratory allergic disorders are a frequent type of allergy with an increasing global incidence, especially for individuals living in urban areas. Viral infections can significantly exacerbate asthma, leading to severe disease courses and possibly fatal consequences. Notably, atopic subjects affected by respiratory allergies such as asthma have a low level of antiviral cytokines. Furthermore, innate immune cells activated by viral pathogens and viruses themselves contribute to the pathogenesis of eosinophilic inflammation. Indeed, the role of viral infections and the innate immune response in respiratory allergy is a growing field of research. This Special Issue, “The Role of Immune Response in Viruses and Respiratory Allergy”, aims at collecting new evidence on immunologic, viral, and host factors contributing to the pathogenesis of respiratory exacerbations. Studies that shed light on the molecular mechanisms of the innate immune response during viremia in atopic subjects are welcome.

Guest Editors

Dr. Mona Rita Yacoub

Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Hospital San Raffaele, 20132 Milan, Italy

Dr. Maria Bernadette Ciloni

Unit of Immunology Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Università Vita-Salute San Raffaele, Milan, Italy

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/164557

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).